Myriad Genetics, Inc.'s Shares Fall on Continued Concern Over Prospects for Lead Drug Candidate

NEW YORK (AP) -- Shares of biotechnology company Myriad Genetics Inc. fell Wednesday on continued concern that the company's Alzheimer's disease drug candidate Flurizan could miss its goal in a late-stage study.